Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | President, R&D and Tech Ops | September 04, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sarepta Therapeutics, Inc.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 203,900 |
Reported balance
After 2026-09-04 transaction · row 1
1 source rowRow 1 · 2026-09-04 · Tax withholding · Disposed 21,423 · Balance 203,900 F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2021 Filed Nov 18, 2021 01:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065314 · doc4.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,898 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. F2 · balance_after: The amount of securities directly owned by the reporting person includes 118 shares of common stock purchased under the Company's Amended and Restated 2013 Employee Stock Purchase Plan on August 31, 2021. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $87.11 | $0.00 |
DisclosureSEC source: 0001209191-21-018421 · doc4.xml · derivative · entry 2 Rodino-Klapac Louise · CIK 0001836218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-03-03 F2 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and becomes exercisable on each monthly anniversary thereafter. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018421 · doc4.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,169 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. Read SEC document |
| March 03, 2021 Filed Mar 11, 2021 01:01 UTC Amendment | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-019666 · doc4a.xml · nonDerivative · entry 2 Rodino-Klapac Louise · CIK 0001836218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,780 F2 · balance_after: On March 5, 2021, the Form 4 filed for the reporting person overstated the number of shares held by the reporting person. This amended form corrects such error by reporting the number of shares withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units on February 28, 2021 and by reporting the corrected total amount of securities directly owned by the reporting person following a grant of restricted stock units on March 3, 2021. F3 · balance_after: The amount of securities directly owned by the reporting person includes 176 shares of common stock purchased under the Company's Amended and Restated 2013 Employee Stock Purchase Plan on February 28, 2021. Read SEC document |
| February 28, 2021 Filed Mar 11, 2021 01:01 UTC Amendment | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 565 | $86.97 | $49,138.05 |
DisclosureSEC source: 0001209191-21-019666 · doc4a.xml · nonDerivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,604 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. F2 · balance_after: On March 5, 2021, the Form 4 filed for the reporting person overstated the number of shares held by the reporting person. This amended form corrects such error by reporting the number of shares withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units on February 28, 2021 and by reporting the corrected total amount of securities directly owned by the reporting person following a grant of restricted stock units on March 3, 2021. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $169.54 | $0.00 |
DisclosureSEC source: 0001209191-20-063360 · doc4.xml · derivative · entry 1 Rodino-Klapac Louise · CIK 0001836218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-12-14 F1 · derivative.exercise_date: Twenty-five percent of the shares of common stock underlying the option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares of common stock underlying such option shall vest and become exercisable on each monthly anniversary of such date of grant thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.